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Psoriatic arthritis
AbstrAct
Objective to report the efficacy, patient-reported, 
radiographic and safety outcomes of 4 years’ certolizumab 
pegol (cZP) treatment in patients with psoriatic arthritis 
(Psa).
Methods raPiD-Psa (nct01087788) was double-blind 
and placebo-controlled to Week 24, dose-blind to Week 
48 and open-label (Ol) to Week 216. Patients were 
randomised 1:1:1 to either placebo or cZP 200 mg every 
2 weeks (Q2W) or 400 mg every 4 weeks (Q4W) (following 
400 mg at Weeks 0/2/4). Patients randomised to cZP 
continued their assigned dose in the Ol period. Patients 
randomised to placebo were re-randomised to cZP 200 mg 
Q2W or 400 mg Q4W (post-loading dose) at Week 16 
(early escape) or after the double-blind phase. We present 
observed and imputed data; missing values were imputed 
using non-responder imputation (nri) for categorical and 
last observation carried forward (lOcF) for continuous 
measures.
Results 409 patients were randomised; 20% (54/273) of 
Week 0 patients randomised to cZP had prior anti-tumour 
necrosis factor (tnF) exposure; 67% (183/273) completed 
216 weeks. By Week 48, 60.4% of patients achieved 
Disease activity index for Psoriatic arthritis low disease 
activity or remission, which was maintained; 66.3% 
achieved these outcomes at Week 216 (nri). at Weeks 
48 and 216, 39.2% of patients achieved minimal disease 
activity (nri). 75% reduction in Psoriasis area and Severity 
index responses were 65% and 52% at Weeks 48 and 
216 (nri). total resolution rates for enthesitis, dactylitis 
and nail psoriasis, at 4 years, were 71%, 81% and 65%, 
respectively (lOcF). Structural damage progression was 
low over 4 years’ treatment. no new safety signals were 
identified after Week 96.
Conclusions cZP efficacy in treating Psa was maintained 
over 4 years, in patients both with and without prior anti-
tnF exposure, with no new safety signals identified.
InTROduCTIOn
Psoriatic arthritis (PsA) is a heterogeneous 
and multifaceted chronic inflammatory 
musculoskeletal disease affecting up to 30% 
of patients with psoriasis.1 2 More than half 
of patients with PsA have a progressive and 
erosive disease, which results in functional 
impairment.3 4 In addition to peripheral joint 
involvement, patients are also affected by skin 
and nail psoriasis, enthesitis and dactylitis. 
Moreover, PsA is associated with numerous 
Key messages
What is already known about this subject?
 ► Previous reports of raPiD-Psa demonstrated the 
efficacy and safety of certolizumab pegol (cZP) 
with two cZP dose regimens over 96 weeks for the 
treatment of psoriatic arthritis (Psa) in patients with 
and without prior anti-tumour necrosis factor (tnF) 
exposure.
What does this study add?
 ► cZP efficacy in patients with and without prior 
anti-tnF exposure and improvements in patient-
reported outcomes, psoriasis, nail disease, 
enthesitis and dactylitis were maintained over 4 
years’ treatment.
 ► Patients completing 4 years’ cZP treatment 
achieved stringent treatment targets: 44% achieved 
Disease activity index for Psoriatic arthritis (DaPSa) 
remission, 32% achieved DaPSa low disease 
activity, 58% achieved minimal disease activity and 
29% achieved very low disease activity.
 ► there was little radiographically detectable 
progression in structural joint damage in 
patients with Psa treated with cZP throughout the 
4-year raPiD-Psa trial.
How might this impact on clinical practice?
 ► the long-term efficacy of cZP in patients with 
and without prior anti-tnF exposure and the 
sustained improvements across most Psa disease 
domains support the use of cZP for the long-term 
therapeutic management of Psa.
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extra-articular immune-mediated symptoms, such as 
uveitis and inflammatory bowel disease, and comorbid-
ities, including cardiovascular disease, obesity, diabetes, 
osteoporosis, cancer, fatty liver disease, anxiety and 
depression. The Group for Research and Assessment of 
Psoriasis and Psoriatic Arthritis (GRAPPA) international 
guidelines for the treatment of PsA have outlined how 
an integrated treatment approach should be taken to 
address the different clinical domains of PsA (periph-
eral arthritis, axial disease, enthesitis, dactylitis and nail 
disease) and comorbidities.5 
Previous reports of RAPID-PsA (NCT01087788), a 
phase 3 double-blind, placebo-controlled trial of CZP in 
patients with PsA, have demonstrated the safety and effi-
cacy of CZP in improving multiple manifestations of the 
disease, including arthritis, skin disease, nail psoriasis, 
dactylitis and enthesitis, while also inhibiting progres-
sion of structural damage and providing improvements 
in patient-reported outcomes (PROs)2 6; CZP efficacy was 
observed from Week 12 (during the double-blind phase) 
and was maintained to Week 96, in patients both with and 
without prior antitumour necrosis factor (TNF) expo-
sure.7 Here, we present the final report of long-term effi-
cacy outcomes of CZP treatment and safety data from the 
4-year RAPID-PsA trial.
MeTHOds
Patients
Patient eligibility criteria for the RAPID-PsA trial have 
been reported elsewhere.2 Briefly, eligible patients 
were ≥18 years, with a diagnosis of active PsA, fulfilling 
the Classification Criteria for Psoriatic Arthritis,8 
of ≥6 months’ duration and had failed treatment 
with ≥1 disease-modifying antirheumatic drug (DMARD). 
Up to 40% of patients could have experienced loss of 
efficacy (secondary failure) or intolerance to one prior 
anti-TNF.
The study protocol, amendments and subject informed 
consent were reviewed by a national, regional or Inde-
pendent Ethics Committee or Institutional Review Board 
prior to implementation. Patients’ informed consent was 
obtained and documented, and the study conducted in 
accordance with local regulations, International Council 
for Harmonisation Good Clinical Practice requirements 
and the ethical principles that have their origin in the 
principles of the Declaration of Helsinki.
study design
RAPID-PsA (NCT01087788) was a 216-week, phase 3, 
randomised, multicentre study in patients with PsA. 
The trial was double-blind and placebo-controlled to 
Week 24, dose-blind to Week 48 and open-label (OL) 
to Week 216. The primary clinical (American College of 
Rheumatology (ACR) 20 at Week 12) and radiographic 
(change from baseline in van der Heijde modified Total 
Sharp Score (mTSS) for PsA9 at Week 24) endpoints 
of RAPID-PsA and interim analyses of the dose-blind 
period (Weeks 24–48) and the first 48 weeks of the OL 
period (ie, 96 weeks from the study start) have been 
reported previously.7 Here, we present data from the 
combined double-blind, dose-blind and OL phase up to 
Week 216.
A total of 409 patients were randomised 1:1:1 to 
placebo or subcutaneous CZP 400 mg at Weeks 0, 2 and 
4 (loading dose) followed by either CZP 200 mg every 
2 weeks (Q2W) or CZP 400 mg every 4 weeks (Q4W) 
(figure 1A). Patients randomised to placebo in the 
dose-blind phase were re-randomised 1:1 to CZP 200 mg 
Q2W or CZP 400 mg Q4W (following CZP loading dose) 
either on failing to achieve ≥10% reduction in tender 
and swollen joint counts at both Weeks 14 and 16 (early 
escape) or after having completed the 24-week double-
blind phase (figure 1A).
study procedures and evaluations
Efficacy assessments included ACR 20/50/70 responder 
rates,10 11 Psoriasis Area and Severity Index (PASI) 
75/90/100 responder rates,10 mean change from base-
line in body surface area (BSA) affected by psoriasis 
and ≤1% BSA responder rates (skin outcomes reported 
in patients with baseline skin involvement ≥3% BSA). The 
Disease Activity Index for Psoriatic Arthritis (DAPSA),12 
the proportion of patients achieving DAPSA low disease 
activity (LDA; DAPSA >4 and ≤14), DAPSA remission 
(DAPSA ≤4), minimal disease activity (MDA; fulfilling at 
least 5 of 7 MDA criteria) and very low disease activity 
(VLDA; achieving all 7 MDA criteria) were also analysed.
Change in nail psoriasis, enthesitis and dactylitis were 
also assessed. Enthesitis was evaluated by mean change 
from baseline in the Leeds Enthesitis Index (LEI)13 and 
total resolution of enthesitis (LEI=0) responder rates for 
patients with baseline involvement (LEI >0). Dactylitis 
was evaluated by mean change from baseline in the Leeds 
Dactylitis Index (LDI)13 and total resolution (LDI=0) 
responder rates for patients with baseline involvement 
(defined as having at least 1 digit affected and with a 
difference in circumference ≥10% compared with the 
opposite digit and LDI >0). Nail psoriasis was evaluated 
by mean change from baseline in the modified Nail 
Psoriasis Severity Index (mNAPSI)13 and total resolution 
(mNAPSI=0) responder rates for patients with baseline 
involvement (mNAPSI >0).
PRO measures included pain (0–100 mm visual 
analogue scale (VAS)),14 fatigue (0–10 VAS),15 function 
(Health Assessment Questionnaire Disability Index, 
HAQ-DI; range: 0 (mild limitations of physical func-
tion)–3 (very severe limitations of physical function)),13 
the Short-Form 36-item health survey (mental compo-
nent summary (MCS) and physical component summary 
(PCS); standardised so that the mean and SD of each 
scale in the USA general population were 50 and 10, with 
higher scores indicating better health-related quality 
of life)16 17 and PsA quality of life (PsAQoL; range: 0 
(best)–20 (worst)).18 Improvements in these PROs were 
evaluated by mean change from baseline.
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Structural joint damage (measured using mTSS) was 
evaluated for patients originally randomised to CZP to 
Week 216 as part of the Week 216 reading campaign, 
which included radiographs taken at baseline, Week 
96, Week 168 and Week 216. Radiographs were also 
read for patients originally randomised to placebo 
who switched to CZP treatment at Week 16 or 24. For 
these patients, mTSS change was assessed from CZP 
initiation. Radiographic images were scored by two 
central readers who were blind to patient information 
and the chronological order of the images. Structural 
joint damage was evaluated as mean change from base-
line mTSS and the proportion of patients with no (or 
minimal) structural joint damage (non-progression; 
defined as change from baseline in mTSS ≤0.5 or ≤0) 
to Week 216. All structural joint damage as described 
above was also evaluated for patients stratified by their 
baseline mTSS into two subgroups (either > or ≤  the 
median baseline mTSS of 4.5).
The Safety Set consisted of patients who received at 
least one dose of CZP at any point during the 216-week 
trial. The occurrence of adverse events (AEs) was 
assessed and recorded at every visit and coded according 
to the Medical Dictionary for Regulatory Activities 
(MedRA) criteria, V.14.1. Treatment-emergent adverse 
events (TEAEs) occurring after the first CZP administra-
tion until 70 days after the last CZP administration were 
recorded.
statistical analysis
Efficacy results for clinical, functional and structural joint 
damage outcomes are presented for patients treated 
with CZP from Week 0 (both doses combined) in this 
manuscript. Data for patients stratified by the dose they 
received and data for the ‘All CZP’ group (all patients 
randomised to CZP at Week 0, combined with patients 
randomised to placebo at Week 0 who were later re-ran-
domised to CZP) are presented in the online supplemen-
tary material.
Enthesitis, dactylitis and nail psoriasis measures (LEI, 
LDI, mNAPSI) are reported for patients affected by the 
respective symptoms at baseline. Missing categorical 
data were imputed by non-responder imputation (NRI), 
except for total resolution of enthesitis, dactylitis and 
nail psoriasis, missing values for which were imputed by 
last observation carried forward (LOCF); missing contin-
uous data were imputed by LOCF for all patients with at 
least a measurement at baseline. Observed data are also 
presented.
Structural joint outcomes were evaluated using a 
mixed-effect model for repeated measures (MMRM),19 
with mTSS as the dependent variable, and where dose 
regimen, visit and their interaction were fixed-effects. 
An unstructured covariance matrix was used to account 
for within-subject correlation. MMRM is a model-based 
approach that was chosen because it allows the use of 
all available data over the course of the study, where any 
missing data are assumed to be missing at random. This is 
done without having to specify a method of imputation. 
Data are presented as the least squares mean with 95% 
confidence intervals (CIs) for mTSS and change from 
baseline in mTSS. The percentage of patients with mTSS 
non-progression are reported based on the observed data 
for patients assessed at each visit.
Figure 1 (A) RAPID-PsA trial design, (B) patient disposition to Week 216 and (C) Kaplan-Meier plot to time of withdrawal for 
any reason, or due to lack of efficacy or adverse events, for patients randomised to CZP at Week 0. †Only 121 of the 123 Week 
0 CZP 200 mg Q2W patients who completed the dose-blind period of treatment went on to start the open-label period of 
treatment. ‡One fewer patient went on to start the open-label period of treatment. *Censored patients are those that withdrew 
due to reasons other than lack of efficacy or adverse event and those lost to follow-up. CZP, certolizumab pegol; Q2W, 
every 2 weeks; Q4W, every 4 weeks; TJC, tender joint count; SJC, swollen joint count.
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Patient withdrawal due to lack of efficacy or AE was esti-
mated using the Kaplan-Meier statistical analysis. Patients 
that withdrew for other reasons and were lost to follow-up 
were censored at the time of withdrawal.
Safety data are presented for the Safety Set. TEAEs are 
reported as the proportion of the Safety Set who experi-
enced each event, and in terms of event rate (ER) per 100 
patient-years (PY) of exposure. Malignancies, including 
lymphoma, were identified using the Standardised 
MedDRA Query (SMQ), ‘Malignancies.’ ‘Infections and 
Infestations’, ‘ Musculoskeletal and Connective Tissue 
Disorders’  and ‘ Cardiac Disorders’ were each identified 
using System Organ Classes (SOCs) of the same name.
ResulTs
Patient disposition and baseline characteristics
There were 409 patients randomised in RAPID-PsA; 273 
were randomised to receive CZP from Week 0 (baseline) 
and 136 to placebo. Baseline demographic and disease 
characteristics of all patients randomised to CZP have 
been published previously and are summarised in online 
supplementary table 1. Among patients randomised to 
placebo, 59 required early escape and were re-randomised 
to CZP at Week 16; 61 completed the double-blind phase 
and were re-randomised to receive CZP at Week 24; 16 
discontinued study treatment prior to re-randomisation 
to CZP (figure 1B). Of the 393 patients who received at 
least one dose of CZP at any time during the RAPID-PsA 
trial, 75 (19%) had prior anti-TNF exposure, 54 (72%) 
of whom were randomised to CZP at Week 0. Baseline 
demographics and disease severity characteristics were 
similar between all patients in the different dosing arms 
as has been reported previously.7
Of the 273 patients randomised to CZP at base-
line, 248 (90.8%) patients completed to Week 24, 237 
(86.8%) patients completed to Week 48 and 183 (67.0%) 
completed to Week 216 (figure 1B). In the combined 
double-blind, dose-blind and OL periods, 36/273 
Figure 2 ACR responder rates in patients receiving CZP from Week 0, stratified by prior anti-TNF exposure (A−C) and the 
proportion of patients receiving CZP from Week 0 achieving MDA (fulfilling ≥5/7 MDA criteria) (D), VLDA (fulfilling 7/7 MDA 
criteria) (E) and DAPSA LDA (>4 and ≤14) or remission (≤4) (F) over 4 years’ CZP treatment. Data are shown for the Randomised 
Set. ACR20/50/70: 20%, 50% and 70% or greater improvement in ACR score. ACR, American College of Rheumatology; CZP, 
certolizumab pegol; DAPSA, Disease Activity Index for Psoriatic Arthritis; LDA, low disease activity; LOCF, last observation 
carried forward; MDA, minimal disease activity; NRI, non-responder imputation; OC, observed case; REM, remission; 
TNF, tumour necrosis factor; VLDA, very low disease activity. 
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(13.2%) and 9/273 (3.3%) patients withdrew from the 
study due to an AE or lack of efficacy, respectively; 45/273 
(16.5%) withdrew for other reasons (figure 1C).
efficacy outcomes
The significant improvements seen in joint disease in 
patients with PsA, as measured by ACR 20/50/70 after 
24 weeks of CZP treatment, were generally maintained 
throughout the dose-blind and OL phases of the 4-year 
study and were similar irrespective of prior anti-TNF 
exposure (online supplementary figure 1, figure 2A–C 
and table 1).
Improvements in disease activity in patients initially 
randomised to CZP, assessed by evaluating the number 
of patients achieving MDA and VLDA (which include 
joint and skin disease components and PROs20) and the 
patients’ DAPSA (a disease activity index based on periph-
eral joint disease, global activity, pain, and CRP levels12), 
were maintained from Week 24 to Week 216 (table 1 and 
figure 2). Of patients completing 4 years’ CZP treatment, 
29% achieved VLDA, more than half achieved MDA and 
more than 75% achieved either DAPSA remission or 
DAPSA LDA (table 1 and figure 2D–F).
Among patients with skin involvement (≥3% BSA) 
at baseline, improvements in psoriasis were gener-
ally maintained from the end of the double-blind 
phase at Week 24 to Week 216, with more than half 
achieving 75% reduction in PASI and BSA ≤1% at 
4 years (figure 3A–B and table 1). Improvements in 
psoriasis were also similar in patients with and without 
prior anti-TNF exposure (online supplementary figure 
2D and online supplementary figure 3D). As expected, 
greater PASI75 and PASI100 responder rates were 
observed and sustained in patients with more severe 
skin involvement at baseline (PASI ≥10 vs PASI <10; 
online supplementary figure 2E and online supplemen-
tary figure 3E).
For patients with enthesitis, dactylitis or nail psoriasis 
at baseline, previously reported improvements achieved 
by Week 24 in LEI, LDI and mNAPSI, respectively, were 
maintained to Week 216 (table 1). More than two-thirds 
of patients treated with CZP, with baseline involvement of 
dactylitis, enthesitis and nail psoriasis, went on to achieve 
total resolution of their respective conditions over 4 years 
(table 1 and figure 3C–E).
Figure 3 PASI responder rates (A, B) and total resolution in (C) nail psoriasis, (D) enthesitis and (E) dactylitis in affected 
patients receiving CZP from Week 0, over 4 years’ treatment. Data are shown for the Randomised Set. PASI responder rates 
are given for patients with baseline skin involvement (≥3% body surface area affected by psoriasis). Total resolution rates for 
nail psoriasis, enthesitis and dactylitis are presented for patients affected by the respective conditions at baseline, respectively 
defined as modified Nail Psoriasis Severity Index >0 for nail psoriasis; Leeds Enthesitis Index >0 for enthesitis and Leeds 
Dactylitis Index >0, defined as having at least 1 digit affected and with a difference in circumference ≥10% compared with the 
opposite digit, for dactylitis. CZP, certolizumab pegol; LOCF, last observation carried forward; NRI, non-responder imputation; 
OC, observed case; PASI, Psoriasis Area and Severity Index.
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Radiographic assessments showed minimal struc-
tural joint damage progression in patients treated with 
CZP from Week 0 to Week 216 (table 2) and in patients 
originally randomised to placebo, who were re-ran-
domised to CZP at Week 16 or 24 (online supplemen-
tary table 5). Patients with baseline mTSS greater than 
the median baseline score (with more severe disease 
than those with a baseline mTSS less than the median) 
also had slightly higher levels of change in mTSS from 
baseline to Week 216, though progression in struc-
tural joint damage remained low in both subgroups 
(online supplementary table 6).
For all measured PROs – HAQ-DI, pain, fatigue, 
PsAQoL, SF-36 PCS and SF-36 MCS – early improve-
ments observed at Week 24 were generally maintained 
or further improved at Week 216 (table 1). The most 
notable improvement was in pain, which improved by 
more than 50% by Week 216.
Improvements in the signs and symptoms of PsA in 
patients treated with CZP over 4 years, by all measures 
evaluated in this study, were similar irrespective of CZP 
dose regimen, and when patients randomised to CZP 
at Week 0 were evaluated together with patients re-ran-
domised from placebo to CZP at Week 16 or 24 (online 
supplementary figures 1–3 and online supplementary 
tables 2–6).
safety
Total exposure to CZP in RAPID-PsA was 1320.8 PY. 
TEAEs occurred in 367 patients (93.4%, ER=257.9 per 
100 PY), the majority of which were mild or moderate. 
Severe TEAEs as classified by the investigator were 
reported in 71 patients (18.1%). Serious TEAEs occurred 
in 100 patients (25.4%, ER=11.9 per 100 PY), and in 27 
cases (6.9%), this led to permanent withdrawal. The most 
common serious TEAEs reported were in the ‘Infections 
and Infestations’,  and ‘Musculoskeletal and Connective 
Tissue Disorders’ SOCs (table 3). The safety profile of 
CZP was similar for both dosing regimens.
Of the 23 infections considered to be serious, the most 
common was pneumonia, with four cases reported; there 
were no confirmed cases of active tuberculosis. Fifty-
four (13.7%) patients experienced a TEAE leading to 
withdrawal from the study. During the study, a total of 
10 patients (2.5%) had a serious cardiac disorder and 7 
patients (1.8%) had a malignancy table 3. There were 3 
reports of breast cancer and single reports of lymphoma, 
metastatic gastrointestinal cancer, ovarian cancer and 
cervix carcinoma stage 0. No cases of uveitis or suicidality 
were reported as TEAEs in this study.
Six deaths occurred during the study, two in the 
double-blind period, one in the dose-blind period and 
three in the OL period between 48 and 96 weeks, which 
have all been reported previously (two cardiac disor-
ders, one sudden death, one infection, one case each of 
breast cancer and lymphoma).7 No further deaths were 
reported, and no new safety signal was identified from 
Week 96 to Week 216.
dIsCussIOn
Two-thirds of the patients originally randomised to CZP 
in the RAPID-PsA trial completed the 4-year study. CZP 
demonstrated long-term efficacy in achieving improve-
ment in disease activity in most of the major disease 
domains of PsA; for most patients completing the trial, 
CZP treatment demonstrated sustained efficacy in 
improving joint disease, skin and nail psoriasis, enthesitis 
and dactylitis, by all disease activity and PRO measures 
assessed, which was similar with both 200 mg Q2W and 
400 mg Q4W dose regimens. The study has shown CZP to 
have a safety profile that is expected for this therapeutic 
class, with the most frequent serious TEAEs being infec-
tions; no new safety signals have been identified since 
the Week 96 report of RAPID-PsA.7
More than 7 in every 10 patients with PsA completing 
4 years' CZP treatment (and 6/10 of the intention-to-
treat population) achieved DAPSA remission or DAPSA 
LDA, which relate to improvements in peripheral joint 
disease and patient reported outcomes. An international 
Table 2 Structural joint damage in patients randomised to 
CZP treatment at Week 0
(A) Change in mTSS from baseline to Week 216 
Week 0 CZP dose 
combined (n=273)
mTSS at baseline 
Observed case (n=269) 
  Mean (SD) 16.03 (34.67) 
  Median 4.50 
  (Min, max) (0, 342.5) 
MMRM estimates, least squares (LS) mean (SE), 95% CI
mTSS at baseline 15.96 (2.24), 11.55 to 20.36
  CFB at Week 96 0.28 (0.12), 0.04 to 0.51
  CFB at Week 168 0.62 (0.19), 0.25 to 0.99
  CFB at Week 216 0.72 (0.20), 0.33 to 1.11
(B) Observed rate of structural joint damage non-
progression at Weeks 96 and 216 
Observed case
Week 0 CZP dose 
combined (n=273)
Time point Week 96 Week 216
Assessed for progression, n 214 186
Rate of non-progression
(CFB in mTSS ≤0.5), n (%)*
180 (84.1) 145 (78.0)
Rate of non-progression
(CFB in mTSS ≤0), n (%)*
157 (73.4) 121 (65.1)
Data are shown for the Randomised Set.
*Percentage is based on the number of participants assessed for 
progression at the visit.
CFB, change from baseline; CZP, certolizumab pegol; LS, least 
squares; MMRM, mixed-effect model for repeated measures; 
mTSS, modified Total Sharp Score.
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taskforce of physicians and patients recently developed 
recommendations for treatment targets in PsA; they 
acknowledged that DAPSA remission may be difficult to 
achieve in patients with long-standing disease, for whom 
they recommend MDA be used as a treatment target.21 
Almost 60% of patients completing 4 years’ CZP treat-
ment had achieved MDA (≥5/7 MDA criteria), and half 
of those also achieved the most stringent target of VLDA 
(7/7 MDA criteria) indicating that CZP can deliver 
low disease activity with respect to articular disease, 
skin disease, pain, function and PROs, for a substantial 
proportion of patients.
There is overlap between the DAPSA and MDA/
VLDA treatment targets; however, the latter also includes 
the domain of skin disease. There are diverse opinions 
regarding whether it is better to assess skin separately 
(in addition to the DAPSA) or as part of the composite 
outcome (such as the MDA/VLDA).22 Psoriasis is a cause 
of frustration and embarrassment in many patients with 
PsA that adds substantially to their burden of disease 
and lessens their quality of life.23 24 CZP demonstrated 
sustained efficacy in improving psoriatic skin disease, 
with more than half of the intention-to-treat population 
in RAPID-PsA with BSA ≥3% at baseline having achieved 
BSA ≤1% at Week 216.
Nail psoriasis, dactylitis and enthesitis also contribute 
significantly to the impact of disease on patients’ quality 
of life.25 RAPID-PsA has demonstrated the sustained, 
long-term efficacy of CZP in improving these symptoms 
of PsA, with more than 6 in every 10 patients with base-
line involvement achieving total resolution of nail psori-
asis, dactylitis and enthesitis.
PROs are important components in the evaluation of 
disease impact and therapy response in patients with 
PsA. The current study showed that patients treated with 
CZP reported improvements for all PROs measured. 
The largest improvement was in pain, which improved 
by more than 50%. Structural joint damage in PsA has 
been associated with disease activity and severity26 and 
often correlates with functional impairment.4 There 
was minimal progression of structural joint damage in 
patients with PsA treated with CZP, as measured by mTSS, 
throughout the 4 years of the RAPID-PsA trial, even in 
patients with more severe structural joint damage at base-
line. The Week 216 radiographic results indicated that 
the proportion of patients treated with CZP over 4 years 
with structural joint damage non-progression from CZP 
baseline remained high. Except for CZP and golimumab, 
such long-term structural joint damage progression data 
have not been reported for other anti-TNFs or other 
biological DMARDs (targeting interleukin-12/17/23) 
Table 3 Treatment-emergent adverse events for all patients treated with CZP during the combined double-blind, dose-blind 
and open-label periods of RAPID-PsA
All CZP* 200 mg 
Q2W (n=198)
All CZP* 400 mg 
Q4W (n=195)
All CZP* dose 
combined (n=393)
n (%) (ER), unless otherwise stated
Exposure to CZP (medication duration, patient-years) 674.4 646.4 1320.8
Any TEAE 184 (92.9) (266.6) 183 (93.8) (248.7) 367 (93.4) (257.9)
  Mild, n (%) 169 (85.4) 167 (85.6) 336 (85.5)
  Moderate, n (%) 132 (66.7) 129 (66.2) 261 (66.4)
  Severe, n (%) 37 (18.7) 34 (17.4) 71 (18.1)
Most common serious TEAEs
  Infections and infestations 13 (6.6) (2.4) 10 (5.1) (2.2) 23 (5.9) (2.3)
  Musculoskeletal and connective tissue disorders 9 (4.5) (1.3) 8 (4.1) (2.0) 17 (4.3) (1.7)
Other adverse events of interest
  Serious cardiac disorders† 8 (4.0) (1.2) 2 (1.0) (0.3) 10 (2.5) (0.8)
  Malignancies‡ 3 (1.5) (0.6) 4 (2.1) (0.6) 7 (1.8) (0.6)
Withdrawals due to TEAEs, n (%) 27 (13.6) 27 (13.8) 54 (13.7)
Serious TEAEs 49 (24.7) (11.7) 51 (26.2) (12.1) 100 (25.4) (11.9)
Withdrawals due to serious TEAEs, n (%) 13 (6.6) 14 (7.2) 27 (6.9)
Deaths§ , n (%) 3 (1.5) 3 (1.5) 6 (1.5)
Data are shown for the Safety Set during the combined double-blind, dose-blind and open-label periods of RAPID-PsA.
*Includes all patients exposed to ≥1 dose of CZP (including patients randomised to placebo re-randomised to CZP).
† Serious cardiac disorders reported are serious TEAEs within the ‘Cardiac Disorders’ system organ class. 
‡ Malignancies, including lymphoma, were identified using the Standardised MedDRA Query, ‘malignancies.’ 
§ Deaths due to cardiac disorders or infection may have been associated with more than one event.
CZP, certolizumab pegol; ER, event rate per 100 patient-years; Q2W, every 2 weeks; Q4W, every 4 weeks; TEAE, treatment-emergent 
adverse event.
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and targeted synthetic DMARDs (phosphodiesterase type 
4 inhibitors) approved for the treatment of PsA. Notably, 
the MMRM analysis used in this study to estimate radio-
graphic progression assumed that the mTSS of patients 
who withdrew from the study would have been statistically 
similar to other patients receiving the same dose regimen 
and who had a similar observed mTSS at baseline, had 
they remained in the study—an assumption that cannot 
be verified based on the available data.
In patients who do not respond adequately to their first 
biological DMARD, the GRAPPA and European League 
Against Rheumatism treatment guidelines for PsA both 
recommend switching to a second biological DMARD; 
including the option to switch between anti-TNFs.5 21 A 
head-to-head trial of  CZP and the anti-TNF adalimumab 
in patients with rheumatoid arthritis recently demon-
strated the efficacy and safety of switching to a second 
anti-TNF after primary failure to an initial anti-TNF.27 
In this study of CZP in patients with PsA, although 
only around 1 in 5 had previously been treated with an 
anti-TNF, the efficacy of CZP was similar in patients both 
with and without prior anti-TNF exposure, indicating 
that CZP may be effective in patients who do not respond 
adequately to their first biological DMARD.
The limitations of the RAPID-PsA study include the 
lack of a placebo control beyond Week 24 and inherent 
bias in having dose-blind and OL periods, when the 
patient is aware that they are receiving active treatment, 
as is their physician. As is true for all clinical trials, 
patient withdrawal from the study also introduces a risk 
of bias in the data, and the impact of patient withdrawal 
is likely to be greater in a long-term study. Imputation 
of the missing data that results from patient withdrawal 
helps to conserve the validity of the analyses, but also 
requires assumptions to be made about the measure-
ments that patients would have had if they had remained 
in the study. Here, we have reported both observed and 
imputed data to minimise the risk of bias. Another limita-
tion of clinical trials is that while the long-term clinical 
efficacy and safety data are relevant to clinical practice, 
the study participants are not completely representative 
of all patients treated in the clinical practice. In conclu-
sion, the 4-year data demonstrating the efficacy of CZP 
across most PsA disease domains in the RAPID-PsA study 
support CZP treatment for the long-term therapeutic 
management of PsA.
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